Imagene Partners with Tempus AI to Develop AI-Powered Diagnostics for NSCLC
Shots:
- Imagene & Tempus AI have collaborated to advance lung cancer diagnostics by enhancing biomarker prediction, integrating AI tools into clinical workflows, & allowing commercial access to diagnostic solutions
- Collaboration will integrate Imagene's AI multi-gene panel for rapid NSCLC biomarker prediction from biopsy images with Tempus' clinical reach & real-world data, creating a unified AI-powered biomarker prediction panel for nationwide commercialization
- The panel will improve biomarker precision & personalized care by providing rapid, accurate NSCLC target predictions (EGFR, ALK, MET, BRAF, HER2, RET, & ROS1) via Tempus' test portfolio while refining Imagene's AI models with real-world data
Ref: Accessnewswire | Image: Imagene & Tempus
Related News:- Avacta Therapeutics Collaborates with Tempus AI to Commence AI-Driven Drug Development in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
